Sherilyn McCoy - AstraZeneca PLC Non-Executive Independent Director
| AZN Stock | USD 68.36 0.17 0.25% |
Director
Ms. Sherilyn S. McCoy serves as NonExecutive Independent Director of the Company effective 1 October 2017. She is retired Chief Executive Officer of Avon Products, Inc. Prior to joining Avon in 2012, Sheri had a distinguished 30year career at Johnson Johnson, latterly serving as Vice Chairman of the Executive Committee, responsible for the Pharmaceuticals and Consumer business segments that represented more than 60 percent of the companys revenues. Sheri joined Johnson Johnson as a scientist in research and development and subsequently managed businesses in every major product sector, including consumer, prescription medicines and medical devices, holding positions including Worldwide Chairman, Surgical Care Group and Division President, Consumer. She holds a BS degree in textile chemistry from the University of Massachusetts Dartmouth, a Masters degree in chemical engineering from Princeton University and an MBA from Rutgers University, both in New Jersey, US. Sheri serves on the boards of Stryker, KimberlyClark and Novocure. She is also an industrial adviser for EQT partners where she chairs Certara, the private company, and is a trustee for Stonehill College, Easton, Massachusetts. since 2017.
| Age | 60 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has Return on Asset of 0.066 % which means that on every $100 spent on assets, it made $0.066 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1564 %, implying that it generated $0.1564 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Christian Mulliez | Sanofi ADR | 57 | |
| Pamela Craig | Merck Company | 64 | |
| Vance Coffman | Amgen Inc | 71 | |
| Klaus Pohle | Sanofi ADR | 76 | |
| Christophe Babule | Sanofi ADR | N/A | |
| Matthew Emmens | Bristol Myers Squibb | 68 | |
| Leslie Brun | Merck Company | 68 | |
| Deryck Maughan | GlaxoSmithKline PLC ADR | 66 | |
| Karen Horn | Eli Lilly and | 71 | |
| Anne Mulcahy | Johnson Johnson | 68 | |
| Andreas Planta | Novartis AG ADR | 65 | |
| Iain Mackay | GlaxoSmithKline PLC ADR | 62 | |
| William Burnside | AbbVie Inc | 69 | |
| Gabrielle Sulzberger | Eli Lilly and | 60 | |
| Ian Davis | Johnson Johnson | 70 | |
| Franklyn Prendergast | Eli Lilly and | 70 | |
| Christine Seidman | Merck Company | 68 | |
| Fabienne Lecorvaisier | Sanofi ADR | 55 | |
| Melanie Lee | Sanofi ADR | 59 | |
| Roy Roberts | AbbVie Inc | 69 | |
| Robert Alpern | AbbVie Inc | 70 | |
Management Performance
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.066 |
AstraZeneca PLC ADR Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, Chief Financial Officer, Executive Director | ||
| Sherilyn McCoy, Non-Executive Independent Director | ||
| Genevieve Berger, Non-Executive Independent Director | ||
| Luke Miels, Executive Vice-President GPPS | ||
| Sean Bohen, Chief Medical Officer, Executive Vice President - Global Medicines Development | ||
| Paul Hudson, Executive Vice President North America | ||
| Nazneen Rahman, Non-Executive Independent Director | ||
| Jose Baselga, Executive Vice President - Research & Development Oncology | ||
| JeanPhilippe Courtois, Non-Executive Independent Director | ||
| Deborah Eldracher, Non-Executive Independent Director | ||
| Thomas Larsen, IR Contact Officer | ||
| Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance Officer | ||
| Tony Mok, Non-Executive Independent Director | ||
| Mark Mallon, Executive Vice President International | ||
| Fiona Cicconi, Executive Vice President - Human Resources | ||
| Deborah DiSanzo, Non-Executive Independent Director | ||
| Chris Sheldon, Head Relations | ||
| Shriti Vadera, Non-Executive Independent Director | ||
| Leif Johansson, Non-Executive Independent Chairman of the Board | ||
| Leon Wang, Executive Vice President - International and China President | ||
| Ann Cairns, Non-Executive Director | ||
| Adrian Kemp, Company Secretary | ||
| Cornelia Bargmann, Non-Executive Director | ||
| Susan MD, Executive Development | ||
| Tim JacksonSmith, Non-Executive Director | ||
| Michel Demare, Non-Executive Independent Director | ||
| Graham Chipchase, Senior Non-Executive Independent Director | ||
| David Smith, Executive VP of Operations and Information Services | ||
| Pascal Soriot, CEO, Executive Director and Member of Disclosure Committee | ||
| Pam Cheng, Executive Vice-President of Operations and Information Technology | ||
| Baroness Vadera, Non-Executive Independent Director | ||
| MBA DVM, CEO Director | ||
| Aradhana MD, CFO Director | ||
| Philip Broadley, Non-Executive Independent Director | ||
| Narayan Seshadri, Independent Director | ||
| Jeffrey Pott, General Counsel | ||
| Ruud Dobber, Executive Vice President, BioPharmaceuticals Business | ||
| David Fredrickson, Executive Vice-President Global Head Oncology Business Unit | ||
| Gonzalo Vina, Head Relations | ||
| Andrew Barnett, Head Relations | ||
| Bahija Jallal, Executive Vice President MedImmune | ||
| Rudolph Markham, Non-Executive Independent Director | ||
| Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticals | ||
| Weiying Wang, Non-Executive Director | ||
| Bruce Burlington, Non-Executive Independent Director | ||
| Marcus Wallenberg, Non-Executive Director | ||
| Iskra Reic, Executive Vice President - Europe and Canada |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.066 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 129.63 B | ||||
| Shares Outstanding | 3.1 B | ||||
| Shares Owned By Institutions | 16.80 % | ||||
| Number Of Shares Shorted | 7.66 M | ||||
| Price To Earning | 103.39 X | ||||
| Price To Book | 5.46 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AstraZeneca PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AstraZeneca PLC's short interest history, or implied volatility extrapolated from AstraZeneca PLC options trading.
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving together with AstraZeneca Stock
| 0.74 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
Moving against AstraZeneca Stock
| 0.75 | VCNX | Vaccinex | PairCorr |
| 0.69 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
| 0.67 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.67 | VCYT | Veracyte Financial Report 2nd of May 2024 | PairCorr |
| 0.67 | DRTS | Alpha Tau Medical Financial Report 28th of May 2024 | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.